Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-014639
Filing Date
2022-05-20
Accepted
2022-05-20 17:00:27
Documents
36
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 291705
2 ex31-1.htm EX-31.1 17459
3 ex32-1.htm EX-32.1 6532
  Complete submission text file 0001493152-22-014639.txt   1582089

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE glsi-20220331.xsd EX-101.SCH 12706
5 XBRL CALCULATION FILE glsi-20220331_cal.xml EX-101.CAL 21947
6 XBRL DEFINITION FILE glsi-20220331_def.xml EX-101.DEF 47455
7 XBRL LABEL FILE glsi-20220331_lab.xml EX-101.LAB 126829
8 XBRL PRESENTATION FILE glsi-20220331_pre.xml EX-101.PRE 102085
30 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 129693
Mailing Address 3992 BLUEBONNET DR, BUILDING 14 STAFFORD TX 77477
Business Address 3992 BLUEBONNET DR, BUILDING 14 STAFFORD TX 77477 203-434-3290
Greenwich LifeSciences, Inc. (Filer) CIK: 0001799788 (see all company filings)

EIN.: 205473709 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39555 | Film No.: 22948533
SIC: 2834 Pharmaceutical Preparations